Published in J Clin Oncol on April 09, 2007
Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients | NCT01402284
A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma | NCT01248455
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004. Br J Haematol (2008) 3.21
Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood (2011) 2.54
Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol (2011) 2.34
Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood (2010) 2.12
Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood (2010) 1.89
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant (2013) 1.88
Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol (2009) 1.88
Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma. Biol Blood Marrow Transplant (2014) 1.55
Second malignancies after multiple myeloma: from 1960s to 2010s. Blood (2012) 1.46
Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica (2009) 1.39
Kidney disease and multiple myeloma. Clin J Am Soc Nephrol (2013) 1.26
Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden. Haematologica (2009) 1.21
Improved long-term survival in multiple myeloma up to the age of 80 years. Leukemia (2014) 1.20
Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. Int J Cancer (2009) 1.12
Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma. J Hematol Oncol (2012) 0.97
TRAF6 activation in multiple myeloma: a potential therapeutic target. Clin Lymphoma Myeloma Leuk (2012) 0.96
Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic. Mayo Clin Proc (2010) 0.96
Incidence and survival in non-hereditary amyloidosis in Sweden. BMC Public Health (2012) 0.96
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. Curr Pharm Des (2013) 0.95
Kidney disease associated with plasma cell dyscrasias. Blood (2010) 0.95
Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial. Leukemia (2010) 0.94
Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica (2014) 0.92
Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia (2013) 0.88
Gender and ploidy in cancer survival. Cell Oncol (Dordr) (2011) 0.88
Changing paradigms in the treatment of multiple myeloma. Haematologica (2009) 0.87
Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies. Clin Biochem Rev (2009) 0.87
Search for familial clustering of multiple myeloma with any cancer. Leukemia (2015) 0.86
Thrombosis is associated with inferior survival in multiple myeloma. Haematologica (2012) 0.86
Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease. Haematologica (2011) 0.84
Diagnosis and therapy of multiple myeloma. Korean J Intern Med (2013) 0.84
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. Haematologica (2015) 0.83
Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008. Cancer (2012) 0.82
Impact of tandem autologous stem cell transplantation and response to transplant in the outcome of multiple myeloma. Exp Hematol Oncol (2012) 0.82
The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma - a Swedish population-based study. BMC Cancer (2015) 0.81
Trends in the incidence and survival of multiple myeloma in South East England 1985-2004. BMC Cancer (2010) 0.81
Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era. Cancer Sci (2015) 0.80
Comparison of the Freiburg and Charlson comorbidity indices in predicting overall survival in elderly patients with newly diagnosed multiple myeloma. Biomed Res Int (2014) 0.79
Survival from multiple myeloma in England and Wales up to 2001. Br J Cancer (2008) 0.79
Long-term survival in multiple myeloma: a single-center experience. Clin Exp Med (2008) 0.79
Clinical use and applications of histone deacetylase inhibitors in multiple myeloma. Clin Pharmacol (2016) 0.78
Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma. Expert Rev Hematol (2010) 0.78
Relationship between circulating syndecan-1 levels (CD138s) and serum free light chains in monoclonal gammopathies. J Exp Clin Cancer Res (2015) 0.78
Development and Validation of an Algorithm to Identify Patients with Multiple Myeloma Using Administrative Claims Data. Front Oncol (2016) 0.78
Frequent down regulation of the tumor suppressor gene a20 in multiple myeloma. PLoS One (2015) 0.78
Pattern of the epitope-specific IgG/IgM response against human cytomegalovirus in patients with multiple myeloma. Clin Vaccine Immunol (2013) 0.77
Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates. Cancer J (2009) 0.77
Treatment patterns and outcomes in elderly patients with multiple myeloma. Leukemia (2012) 0.76
Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen. BMC Cancer (2016) 0.76
Advances in current treatment for patients with newly diagnosed multiple myeloma. Leuk Suppl (2013) 0.75
History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study. Ann Hematol (2016) 0.75
Evolving prevalence of haematological malignancies in orphan designation procedures in the European Union. Orphanet J Rare Dis (2017) 0.75
Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant (2016) 0.75
Lenalidomide in renal insufficiency--balancing the risks and benefits. Br J Haematol (2008) 0.75
Immunogenic targets for specific immunotherapy in multiple myeloma. Clin Dev Immunol (2012) 0.75
Multiple myeloma revealed by spinal cord compression and herpes zoster in a 36-year-old Cameroonian. Pan Afr Med J (2013) 0.75
Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations. Leuk Res Rep (2015) 0.75
Incidence and risk factors for suicide and attempted suicide following a diagnosis of hematological malignancy. Cancer Med (2014) 0.75
Successful use of cyclophosphamide as an add-on therapy for multiple myeloma patients with acquired resistance to bortezomib or lenalidomide. Case Rep Hematol (2013) 0.75
Advances in treatment for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation. Leuk Suppl (2013) 0.75
Efficacy of lenalidomide in association with cyclophosphamide and dexamethasone in multiple myeloma patient with bilateral retro-orbital localisation. Ecancermedicalscience (2013) 0.75
Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol (2016) 0.75
Partial remission of acute myeloid leukemia complicating multiple myeloma following COAP chemotherapy: A case report. Oncol Lett (2015) 0.75
Statin use and risk of multiple myeloma: An analysis from the Cancer Research Network. Int J Cancer (2017) 0.75
Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. Haematologica (2017) 0.75
Multiple Myeloma Cells Express Key Immunoregulatory Cytokines and Modulate the Monocyte Migratory Response. Front Med (Lausanne) (2017) 0.75
The role of initial clinical presentation, comorbidity and treatment in multiple myeloma patients on survival: a detailed population-based cohort study. Eur J Clin Pharmacol (2017) 0.75
Natural history of early, localized prostate cancer. JAMA (2004) 7.44
Quality of life after radical prostatectomy or watchful waiting. N Engl J Med (2002) 6.83
Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004. Br J Haematol (2008) 3.21
Feasibility of using web-based questionnaires in large population-based epidemiological studies. Eur J Epidemiol (2006) 2.86
Solid cancers after allogeneic hematopoietic cell transplantation. Blood (2008) 2.56
Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood (2011) 2.54
Reasons for increasing trends in large for gestational age births. Obstet Gynecol (2004) 2.54
Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA (2007) 2.51
Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer (2006) 2.46
Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol (2011) 2.34
Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. Int J Cancer (2007) 2.16
Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood (2010) 2.12
Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol (2011) 2.11
Control of autophagic cell death by caspase-10 in multiple myeloma. Cancer Cell (2013) 2.06
Chronic lymphocytic leukaemia: an overview of aetiology in light of recent developments in classification and pathogenesis. Br J Haematol (2007) 2.02
Free light chains and the risk of AIDS-defining opportunistic infections in HIV-infected individuals. Clin Infect Dis (2012) 2.01
Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer (2009) 2.01
Previous preterm and small-for-gestational-age births and the subsequent risk of stillbirth. N Engl J Med (2004) 1.95
Activation of telomerase by human cytomegalovirus. J Natl Cancer Inst (2009) 1.92
Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood (2010) 1.89
Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol (2009) 1.88
Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. Hepatology (2009) 1.80
Differences in management of older women influence breast cancer survival: results from a population-based database in Sweden. PLoS Med (2006) 1.79
Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood (2008) 1.78
Minimal residual disease: what are the minimum requirements? J Clin Oncol (2014) 1.76
Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol (2007) 1.68
Risk factors for hormone receptor-defined breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev (2006) 1.66
Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood (2013) 1.64
The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy. Haematologica (2006) 1.63
Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood (2008) 1.61
The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica (2006) 1.59
Hematopoietic malignancies associated with viral and alcoholic hepatitis. Cancer Epidemiol Biomarkers Prev (2008) 1.59
Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol (2007) 1.54
Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase. Leuk Lymphoma (2006) 1.52
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol (2014) 1.52
Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol (2011) 1.51
Optimizing the design of web-based questionnaires--experience from a population-based study among 50,000 women. Eur J Epidemiol (2007) 1.51
Concomitant and antecedent deep venous thrombosis and cancer survival in male US veterans. Leuk Lymphoma (2011) 1.50
Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia. Haematologica (2009) 1.50
Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma. Arthritis Rheum (2008) 1.50
Immunologic and virologic predictors of AIDS-related non-hodgkin lymphoma in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr (2010) 1.47
Second malignancies after multiple myeloma: from 1960s to 2010s. Blood (2012) 1.46
Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol (2012) 1.46
Familial aggregation and heterogeneity of non-Hodgkin lymphoma in population-based samples. Cancer Epidemiol Biomarkers Prev (2005) 1.45
Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol (2002) 1.43
Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib. Leuk Lymphoma (2014) 1.43
CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res (2008) 1.42
Parity and risk of later-life maternal cardiovascular disease. Am Heart J (2010) 1.41
Does granulocyte colony-stimulating factor improve long-term outcome in adult acute lymphoblastic leukemia? Leuk Lymphoma (2009) 1.41
Borrelia and subsequent risk of solid tumors and hematologic malignancies in Sweden. Int J Cancer (2012) 1.39
Cancer risk among patients with myotonic muscular dystrophy. JAMA (2011) 1.38
Serum free light chains as predictors of lymphomagenesis in patients with autosomal dominant hyper-immunoglobulin E syndrome (Job's syndrome). Leuk Lymphoma (2012) 1.38
Increased risk for non-Hodgkin lymphoma in individuals with celiac disease and a potential familial association. Gastroenterology (2008) 1.36
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol (2003) 1.33
Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study. Breast Cancer Res (2006) 1.29
Autoimmunity and lymphomagenesis. Int J Cancer (2009) 1.29
The histone demethylase RBP2 Is overexpressed in gastric cancer and its inhibition triggers senescence of cancer cells. Gastroenterology (2009) 1.29
IMWG consensus on maintenance therapy in multiple myeloma. Blood (2012) 1.29
Patient-rating of distressful symptoms after treatment for early cervical cancer. Acta Obstet Gynecol Scand (2002) 1.28
Estimating and modeling the cure fraction in population-based cancer survival analysis. Biostatistics (2006) 1.27
Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood (2013) 1.27
FoxM1 is up-regulated in gastric cancer and its inhibition leads to cellular senescence, partially dependent on p27 kip1. J Pathol (2009) 1.27
Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst (2002) 1.26
Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans. Cancer (2010) 1.25
Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica (2010) 1.25
Estimating net survival in population-based cancer studies. Int J Cancer (2013) 1.24
Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. J Natl Cancer Inst (2010) 1.24
Time of birth and risk of intrapartum and early neonatal death. Epidemiology (2003) 1.22
Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden. Haematologica (2009) 1.21
The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells. Exp Cell Res (2002) 1.21
Myeloma and second primary cancers. N Engl J Med (2011) 1.20
Is breast cancer prognosis inherited? Breast Cancer Res (2007) 1.20
Some life-style factors and the risk of invasive epithelial ovarian cancer in Swedish women. Eur J Epidemiol (2004) 1.20
Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica (2009) 1.19